Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.47 0.28 −10.18%
Market cap
$422.3M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
218.07 128.07 163.90 176.89
Total non-current assets
19.30 21.27 22.64 24.86
Total Assets
237.36 149.34 186.53 201.75
Total current liabilities
68.43 39.78 46.25 61.77
Total non-current liabilities
63.65 105.15 113.00 126.53
Total liabilities
132.08 144.93 159.25 188.30
Common Equity (Total)
105.28 4.41 27.29 13.45
Shareholders Equity (Total)
105.28 4.41 27.29 13.45

Show all line items

In millions of $ except per-share values · columns are period end dates